Provided by Tiger Trade Technology Pte. Ltd.

Entrada Therapeutics, Inc.

6.42
-0.6900-9.70%
Post-market: 6.420.00000.00%16:10 EDT
Volume:448.06K
Turnover:2.94M
Market Cap:249.23M
PE:-1.62
High:7.18
Open:7.00
Low:6.38
Close:7.11
52wk High:16.45
52wk Low:5.02
Shares:38.82M
Float Shares:22.72M
Volume Ratio:1.15
T/O Rate:1.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9676
EPS(LYR):-3.4746
ROE:-54.09%
ROA:-29.20%
PB:1.07
PE(LYR):-1.85

Loading ...

Entrada Therapeutics: Initiated Dosing of Elevate-44-201 Cohort 2 at Increased Dose of 12 Mg/Kg, on Track to Report Data by Year-End 2026

THOMSON REUTERS
·
May 07

Entrada Therapeutics: Cohort 1 Showed 2.36% Increase in Dystrophin Over 4.00% Baseline in Treated Participants

THOMSON REUTERS
·
May 07

Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026

GlobeNewswire
·
May 07

Entrada R&D President Sethuraman Natarajan sells 25,907 shares worth $398,684.79

Reuters
·
May 05

Entrada President, COO Nathan Dowden disposes of shares worth $229,953 at Entrada Therapeutics

Reuters
·
May 05

Entrada Therapeutics Inc expected to post a loss of $1.04 a share - Earnings Preview

Reuters
·
May 04

Entrada Therapeutics announces annual shareholder meeting

Reuters
·
Apr 24

Guggenheim Keeps Their Buy Rating on Entrada Therapeutics Inc (TRDA)

TIPRANKS
·
Apr 24

Entrada publishes corporate deck outlining DMD, DM1 pipeline catalysts and $5 billion US market opportunity

Reuters
·
Apr 07

Entrada Therapeutics Q2 Data Could Drive Platform Differentiation, Oppenheimer Says

MT Newswires Live
·
Apr 07

Entrada Therapeutics Is Maintained at Outperform by Oppenheimer

Dow Jones
·
Apr 06

Oppenheimer Adjusts Price Target on Entrada Therapeutics to $23 From $21, Maintains Outperform Rating

MT Newswires Live
·
Apr 06

Entrada Therapeutics, Inc. : Oppenheimer Raises Target Price to $23 From $21

THOMSON REUTERS
·
Apr 06

U.S. RESEARCH ROUNDUP-EQT, Las Vegas Sands, Twilio

Reuters
·
Apr 06

Entrada CFO Kory James Wentworth sells $0 million Entrada Therapeutics common shares

Reuters
·
Apr 03

Cantor Fitzgerald Initiates Coverage on Entrada Therapeutics With Overweight Rating

MT Newswires Live
·
Apr 01

Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA), Apellis Pharmaceuticals (APLS) and MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Apr 01